Stockreport

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory...

Minerva Neurosciences, Inc  (NERV) 
Last minerva neurosciences, inc earnings: 3/9 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.minervaneurosciences.com/investor-relations
PDF   Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants.Minerva and the FDA have defined a path fo [Read more]